Blair William & Co. IL Grows Stock Position in Abbott Laboratories (NYSE:ABT)

Blair William & Co. IL raised its stake in shares of Abbott Laboratories (NYSE:ABTGet Rating) by 4.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,900,866 shares of the healthcare product maker’s stock after buying an additional 83,276 shares during the period. Abbott Laboratories comprises about 0.8% of Blair William & Co. IL’s portfolio, making the stock its 25th largest holding. Blair William & Co. IL owned 0.11% of Abbott Laboratories worth $267,528,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Bedel Financial Consulting Inc. grew its position in Abbott Laboratories by 3.2% during the fourth quarter. Bedel Financial Consulting Inc. now owns 2,496 shares of the healthcare product maker’s stock valued at $351,000 after purchasing an additional 77 shares in the last quarter. Webster Bank N. A. grew its position in Abbott Laboratories by 0.8% during the fourth quarter. Webster Bank N. A. now owns 10,473 shares of the healthcare product maker’s stock valued at $1,474,000 after purchasing an additional 78 shares in the last quarter. Sequent Asset Management LLC grew its position in Abbott Laboratories by 1.3% during the fourth quarter. Sequent Asset Management LLC now owns 6,086 shares of the healthcare product maker’s stock valued at $856,000 after purchasing an additional 80 shares in the last quarter. Centaurus Financial Inc. grew its position in Abbott Laboratories by 1.2% during the fourth quarter. Centaurus Financial Inc. now owns 6,878 shares of the healthcare product maker’s stock valued at $968,000 after purchasing an additional 80 shares in the last quarter. Finally, Innovative Portfolios grew its position in Abbott Laboratories by 3.2% during the fourth quarter. Innovative Portfolios now owns 2,608 shares of the healthcare product maker’s stock valued at $367,000 after purchasing an additional 81 shares in the last quarter. Institutional investors and hedge funds own 73.46% of the company’s stock.

NYSE:ABT traded down $1.26 during trading hours on Tuesday, hitting $113.77. 4,925,690 shares of the company traded hands, compared to its average volume of 6,021,178. The stock has a market capitalization of $199.20 billion, a price-to-earnings ratio of 26.40, a P/E/G ratio of 3.05 and a beta of 0.73. Abbott Laboratories has a twelve month low of $104.63 and a twelve month high of $142.60. The firm has a 50-day moving average of $116.84 and a 200 day moving average of $124.00. The company has a current ratio of 1.85, a quick ratio of 1.40 and a debt-to-equity ratio of 0.48.

Abbott Laboratories (NYSE:ABTGet Rating) last released its earnings results on Wednesday, April 20th. The healthcare product maker reported $1.73 EPS for the quarter, beating the consensus estimate of $1.47 by $0.26. The firm had revenue of $11.90 billion during the quarter, compared to analysts’ expectations of $11 billion. Abbott Laboratories had a net margin of 17.35% and a return on equity of 28.72%. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.32 EPS. Equities research analysts predict that Abbott Laboratories will post 4.7 earnings per share for the current fiscal year.

In other news, SVP Randel William Woodgrift sold 964 shares of the company’s stock in a transaction dated Tuesday, March 1st. The shares were sold at an average price of $118.10, for a total value of $113,848.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nancy Mckinstry sold 1,614 shares of the company’s stock in a transaction dated Thursday, February 24th. The stock was sold at an average price of $116.42, for a total transaction of $187,901.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 81,034 shares of company stock valued at $9,196,618. Corporate insiders own 0.52% of the company’s stock.

Several research firms have commented on ABT. StockNews.com began coverage on shares of Abbott Laboratories in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. UBS Group boosted their target price on shares of Abbott Laboratories from $138.00 to $142.00 and gave the stock a “buy” rating in a research report on Thursday, January 27th. Citigroup decreased their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set a “na” rating for the company in a research report on Tuesday, May 17th. Wells Fargo & Company decreased their target price on shares of Abbott Laboratories from $155.00 to $150.00 and set an “overweight” rating for the company in a research report on Friday, April 8th. Finally, Raymond James decreased their target price on shares of Abbott Laboratories from $143.00 to $135.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. Three equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Buy” and an average price target of $137.89.

Abbott Laboratories Company Profile (Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Further Reading

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTGet Rating).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.